Source:http://linkedlifedata.com/resource/umls/id/C1452684
PDQ: A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. PXD101 targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. PDX101 may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454583&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=454583&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48812" NCI Thesaurus)